| Answers |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Investing > Uranium: The New Precious Metal |
|
Answers - Uranium: The New Precious Metal
Newly mined uranium remains ‘highly sought after’ maintains Nuclear Market Review (NMR) editor Treva Klingbiel in the February 23rd issue of the weekly trade magazine, servicing the utility and nuclea According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product r fuel industry. It was no more evident than at this past week’s spot auction for U.S.-mined uranium. The record $10/pound price increase, reaching a new spot uranium record of US$85/pound, was, acco ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ding to Klingbiel, “the single largest (dollar) increase recorded since prices were first published in 1968.” TradeTech posts the weekly spot uranium price, as reported in NMR, on the consulting servi lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. e’s website. At US$85/pound, it has occurred to us that uranium oxide concentrate has now begun to approach ‘precious metal’ status at $5.31/ounce, or 17.4 cents/gram. It is reminiscent of the silver here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe price, which last traded around this level in August 2003. Metals become precious when there is a scarcity of available supply. A modest sum of 100,000 pounds of U3O8 was offered (again) by Mestena U d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro anium LLC, a privately held uranium miner in Texas. According to a February 13th quarterly report, published by the Energy Information Administration (EIA), annual production capacity at Mestena’s Alt ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc Mesa in situ recovery (ISR) operation is one million pounds. The material auctioned this past week could represent as much as 10 percent of the company’s potential product to be offered at auction du easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ing 2007. Because the majority of other uranium supply is being offered with ‘market-related pricing terms’ at the time of delivery, a fixed delivery price has now become the rage among utilities and nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically speculators. “Bidding was extremely aggressive with a record number of bidders vying to purchase the material,” wrote Klingbiel. “Higher prices have not deterred potential buyers.” The spot uranium m and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ rket has come to rely on the Mestena sealed-bid auctions for longer-term price guidance. “Public auctions were a key factor in the price rise witnessed last year and clearly will continue to be instru ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ental in price formation during 2007,” Klingbiel wrote. “The year 2007 may well eclipse the extraordinary price increases witnessed last year.” Long-term demand for U3O8 now exceeds 54 million pounds ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a This past week, a non-U.S. utility requested offers to buy two million pounds U3O8 for delivery starting in 2008. Prior to this request, 15 utilities were evaluating offers or seeking to purchase nea dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ly 54 million pounds, according to NMR. The record price has also encouraged higher uranium production at U.S.-based facilities, such as Mestena. In its quarterly report, preliminary EIA data suggest cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin d total U.S. uranium concentrate production of 4.1 million pounds – a 53-percent increase in production over 2005. Douglas Bonner, who prepared the EIA report, wrote, “This is the highest (annual) pro tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen uction level since 1999.” We believe this strong annual production level came mainly from Wyoming’s Smith Ranch-Highland and Nebraska’s Crow Butte ISR uranium mines. The in situ recovery (ISR) operat t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ons produced a record 2.7 million pounds U3O8. These operations contributed nearly 13 percent of Cameco’s worldwide mining production in 2006. The balance of 2006 uranium production came from Mestena ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust nd Uranium Resources, both based in Texas. Fourth quarter 2006 production was reportedly 78 percent higher than 4Q 2005. This was the highest quarterly production level since the fourth quarter of 19 y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products 7. U.S. concentrate production this past year was 76 percent higher than at the nadir of the domestic uranium-mining depression in 2002. Despite this increase, the U.S. uranium mining industry only pr . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de duces about seven percent of the raw product that nuclear fuel U.S. utilities consume each year. Nuclear utilities rely upon foreign-mined uranium and dwindling stockpiled inventories to power the cou elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip try’s 103 nuclear reactors. The next official U.S. government statistical report on U.S. uranium production will be released on May 17th. COPYRIGHT © 2007 by StockInterview, Inc. ALL RIGHTS RESERVED tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:The Presentation After the Presentation Important Considerations For Drop Shipping
|